First OTC drug approved for women with overactive bladder

January 25, 2013

(HealthDay)—The drug Oxytrol has been approved by the U.S. Food and Drug Administration as the first over-the-counter treatment for women 18 and older with overactive bladder.

is characterized by symptoms including leakage, frequent urination and feeling the sudden and urgent need to urinate. The condition affects some 33 million Americans, mostly older women.

Oxytrol contains oxybutynin, among a class of drugs called anticholinergics that are designed to relax the . Oxytrol is a patch applied to the skin every four days, the FDA said in a news release.

The drug will remain available for adult men by prescription only, the agency said.

Side effects reported during clinical testing included skin irritation at the patch site, dry mouth and constipation.

Oxytrol for Women is marketed by Merck, based in Whitehouse Station, N.J.

Explore further: Myrbetriq approved for overactive bladder

More information: To learn more about overactive bladder, visit the U.S. Department of Health and Human Services.

Related Stories

Myrbetriq approved for overactive bladder

June 28, 2012
(HealthDay) -- Myrbetriq (mirabegron) has been approved to treat adults with overactive bladder, a condition affecting some 33 million Americans, the U.S. Food and Drug Administration said Thursday in a news release.

FDA gives nod to botox to treat overactive bladder

January 19, 2013
(HealthDay)—The U.S. Food and Drug Administration on Friday gave its approval for the use of Botox against a form of urinary incontinence known as overactive bladder.

Drug treatment for urinary incontinence effective, but side-effects can derail success

April 9, 2012
Women with UI suffer physical, psychological, and social consequences of not being in full control of their bladders.

Drug patch approved for advanced Parkinson's and restless leg syndrome

April 3, 2012
(HealthDay) -- The Neupro (rotigotine) transdermal system has been approved by the U.S. Food and Drug Administration to treat advanced Parkinson's disease and moderate-to-severe restless leg syndrome, the Belgian drug maker ...

Overactive bladder linked to sleep apnoea in women

September 3, 2012
Sleep apnoea in women has been linked to overactive bladder syndrome in a new study.

Bladder 'pacemaker' can fix overactive bladder, other voiding issues

April 29, 2011
If your day is punctuated by urgent trips to the bathroom or trouble emptying your bladder, you might have a voiding dysfunction condition. The good news is that it can be easily treated.

Recommended for you

Fighting opioid addiction in primary care—new study shows it's possible

October 18, 2017
For many of the 2 million Americans addicted to opioids, getting good treatment and getting off prescription painkillers or heroin may seem like a far-off dream.

With no morphine, 25 million die in pain each year: report

October 13, 2017
Every year, some 25 million people—one in ten of them children—die in serious pain that could have been alleviated with morphine at just a few cents per dose, researchers said Friday.

Study finds few restrictions on Rx opioids through Medicare

October 9, 2017
Medicare plans place few restrictions on the coverage of prescription opioids, despite federal guidelines recommending such restrictions, a new Yale study finds. The research results highlight an untapped opportunity for ...

Nocebo effect: Does a drug's high price tag cause its own side effects?

October 5, 2017
Pricey drugs may make people more vulnerable to perceiving side effects, a new study suggests—and the phenomenon is not just "in their heads."

Pre-packaged brand version of compounded medication to prevent preterm births costs 5,000 percent more

October 2, 2017
Preventing a preterm birth could cost as little as $200 or as much as $20,000, depending on which one of two medications a doctor orders, according to a new analysis from Harvard Medical School.

Cancer drugs' high prices not justified by cost of development, study contends

September 12, 2017
(HealthDay)— Excusing the sky-high price tags of many new cancer treatments, pharmaceutical companies often blame high research and development (R&D) costs.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.